KORU Medical Systems, Inc. 8-K

What Happened KORU Medical Systems, Inc. (KRMD) announced an Amendment No. 1 to its Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, LLC, effective June 24, 2026. The Amendment extends the agreement’s initial term to expire on December 31, 2031 (with automatic one-year renewals unless a 180‑day notice is given), revises pricing and payment terms, and addresses rights and obligations related to a required second manufacturing site.

Key Details

• The Amendment is effective June 24, 2026 and extends the initial term to December 31, 2031; the agreement will auto-renew for successive one-year periods unless a party gives at least 180 days’ notice.
• Command must obtain and qualify a second manufacturing site by December 31, 2027; KORU has the right to terminate if Command fails to meet this requirement and does not cure within 30 days.
• Pricing and payment terms were modified, including product pricing, annual price adjustments, and application of pass-through cost savings.
• The Amendment designates Command as the exclusive manufacturer for a limited set of products, clarifies intellectual property ownership and licenses, makes assignment rights mutual, and removes a non-competition provision.

Why It Matters This amendment governs how KORU will source key subassemblies, needle sets and tubing products, and sets the commercial and operational framework through at least the end of 2031. The revised pricing terms and pass-through cost treatment could affect the company’s product costs and margins. The second-site qualification requirement and exclusivity for certain products are important for supply-chain resilience and concentration risk: KORU gained a contractual right to terminate if Command does not qualify a second site by the 2027 deadline. Investors should view this as a material supplier agreement update affecting manufacturing, costs and operational continuity.